IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
Recruitment status was: Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Kidney Diseases Graft Rejection | Drug: Tacrolimus Drug: Rapamycin | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Comparative Study of Tacrolimus and Rapamycin to Evaluate the Renal Function in Patients Older Than 50 Years, Receptors of a Kidney From a Donor Older Than 55 Years in a Mycophenolate Mofetil and Daclizumab Immunosuppressor Regime |
- Serum creatinine at 6 months
- Calculated creatinine clearance (Cockroft Gault)
- Acute rejection rate at 6 months and time until first rejection
- Patient and graft survival at 6 months
- Rate and length of the delay in the graft function defined as dialysis in the first week post-transplant
- Treatment failure at 6 months
| Estimated Enrollment: | 94 |
The study population characteristics raise the need to establish a treatment regime that assures suitable intensity immunosuppression to avoid the appearance of rejection episodes, but minimizes the doses to prevent over-immunosuppression in a population with a theoretic minor immune response.
On the other hand, the delay in the introduction of calcineurin inhibitors will prevent increasing the risk of early graft dysfunction allowing the highest post-transplant renal recovery in organs with less operative mass and greater sensibility to the nephrotoxic effect of these drugs.
The results of several studies confirm the goodness of regimes that include low doses of calcineurin inhibitors, delay their introduction or avoid them.
Nevertheless, although it is standard practice to evaluate the effectiveness of the regimes for a time to assure, with certainty, the response to the treatments, these follow-ups are still relatively short to assure the efficacy for a long-term study and to detect the problems. The studies with a high number of patients and long follow-up periods are difficult, so several authors have proposed different alternatives of control in a short-term study that could be useful as surrogate markers or predictive efficacy variables for the long term.
If the drug or study regime is efficient, the observed change after the transplantation surgery will have to be fast and objective. The increase of serum creatinine between 6 and 12 months post-transplant is a reliable marker of graft failure risk, and the magnitude of the serum creatinine change in these months is a marker of the relationship with long-term survival. For that reason, renal function (serum creatinine) is included as a main efficacy variable.
Eligibility| Ages Eligible for Study: | 50 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Both male and female patients older than 50 years who are primary recipients of a renal allograft from a donor older than 55 years.
- Patients who have given their consent previously to their participation in the study.
Exclusion Criteria:
- Recipients of a multi-organ transplant.
- Recipients of a transplant from a cadaveric donor with a cold ischemic time > 30 hours.
- Patients with a plasma renin activity (PRA) > 20% in 6 months previous to the inclusion.
- Breast-feeding, pregnant, or fertile women who do not use a reliable anticonceptive method before starting therapy with the study drug, during the therapy, and during the 4 months after the last dose of the drugs administered in the study.
- Patients with leukocyte count < 2.5 x 10^9/L, platelet count < 100 x 10^9/L, or haemoglobin < 6 g/dL in the inclusion time
- Patients with active hepatic illness evidence.
- Patients with active peptic ulcer.
- Patients with serious diarrhoea or any intestinal upset that may interfere in the absorption capability of oral medication, including diabetic patients with previously diagnosticated diabetic gastroenteropathy.
- Patients with evidence of active systemic infection that require the continued use of antibiotics or evidence of HIV infection or hepatitis B presence (positive HBs-Ag) or active chronic hepatitis C.
- Patients with malignancy history (except satisfactorily treated non- melanocytic localized skin cancer and cervix "in situ" carcinoma).
- Patients with history of psychologic disease that may interfere in the patients capability to understand the study requirements.
-
Patients who the investigator thinks need a treatment with any medication listed below:
- Azathioprine,
- Methotrexate,
- Cyclofosfamide,
- Polyclonal or monoclonal anti-lymphocitaries antibodies (OKT3, ATG), used for the induction in patients with high immunologic risk,
- Basiliximab, and
- Other research drugs
- Known hypersensibility or complete contraindication of any of the drugs administered in the study context or any other substance present in the study drugs.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00290069
| Spain | |
| Complejo Hospitalario Universitario de Santiago | Not yet recruiting |
| Santiago de Compostela, La Coruña, Spain, 15706 | |
| Contact: Rafael Romero, MD | |
| Principal Investigator: Rafael Romero, MD | |
| Hospital General Universitario Gregorio Marañón | Not yet recruiting |
| Madrid, Spain, 28007 | |
| Contact: Fernando Anaya, MD | |
| Principal Investigator: Fernando Anaya, MD | |
| Hospital Universitario Ramón y Cajal | Not yet recruiting |
| Madrid, Spain, 28034 | |
| Contact: Roberto Marcén, MD | |
| Principal Investigator: Roberto Marcén, MD | |
| Hospital Universitario 12 de Octubre | Not yet recruiting |
| Madrid, Spain, 28041 | |
| Contact: José L Morales, MD | |
| Principal Investigator: José L Morales, MD | |
| Hospital Universitario de Canarias | Not yet recruiting |
| Santa Cruz de Tenerife, Spain, 38320 | |
| Contact: Domingo Hernández, MD | |
| Principal Investigator: Domingo Hernández, MD | |
| Hospital Universitario Marqués de Valdecilla | Not yet recruiting |
| Santander, Spain, 39008 | |
| Contact: Juan C Ruiz San Millán, MD | |
| Principal Investigator: Juan C Ruiz San Millán, MD | |
| Hospital Universitario La Fe | Not yet recruiting |
| Valencia, Spain, 46009 | |
| Contact: Jaime Sánchez Plumed, MD | |
| Principal Investigator: Jaime Sánchez Plumed, MD | |
| Principal Investigator: | Miguel A Gonzalez Molina, MD | Sociedad Andaluza de Trasplantes de Organos y Tejidos |
More Information
| ClinicalTrials.gov Identifier: | NCT00290069 History of Changes |
| Other Study ID Numbers: |
SATOT42005 EudraCT number: 2005-001854-25 ALHAMBRA |
| Study First Received: | February 9, 2006 |
| Last Updated: | May 14, 2007 |
Keywords provided by Sociedad Andaluza de Trasplantes de Organos y Tejidos:
|
Renal function Serum creatinine Immunosuppression Rejection |
Additional relevant MeSH terms:
|
Kidney Diseases Urologic Diseases Tacrolimus Mycophenolate mofetil Sirolimus Everolimus Mycophenolic Acid Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Calcineurin Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antibiotics, Antineoplastic Antineoplastic Agents Anti-Bacterial Agents Anti-Infective Agents Antifungal Agents |
ClinicalTrials.gov processed this record on June 26, 2017